The breakdown of the fair value of plan assets is as follows: (Millions of yen) 1 April 2012  (Transition date) 2013 2014 Japan Equity ¥ 33,409 ¥ 36,280 ¥ 26,787 Bonds 39,934 47,956 42,730 Cash and other investments 20,534 20,031 42,201 Total 93,877 104,268 111,719 Overseas Equity 11,415 12,305 14,153 Bonds 12,067 16,757 20,685 Cash and other investments 3,364 4,199 5,066 Total 26,846 33,262 39,904 Total fair value of plan assets ¥120,723 ¥137,530 ¥151,623 2. Overseas plan assets 1. Japanese plan assets Equity and bonds are mainly composed of investments with  quoted prices in active markets, and they are mainly categorised  as Level 1 within the fair value hierarchy. Equity comprises mainly investment trust funds and it is  categorised as Level 2 within the fair value hierarchy. The fair values of bonds are measured using quoted prices  for identical or similar assets in markets that are not active, and  they are categorised as Level 2 within the fair value hierarchy. Cash and other investments include alternative investments. Cash and other investments include alternative investments. Significant actuarial assumptions and sensitivity analysis for each significant actuarial assumption are as follows: are held constant. In practice, changes in some of the  assumptions may occur in a correlated manner. When calcu- lating the sensitivity of the defined benefit obligations, the  same method has been applied as calculating the defined  benefit obligations recognised in the consolidated statements  of financial position. A 0.5% increase or decrease in the discount rate as significant  actuarial assumption would lead to a ¥12,560 million decrease  and ¥14,026 million increase, respectively, in the defined  benefit obligation. The sensitivity analysis does not consider correlations  between assumptions, assuming that all other assumptions  The weighted-average duration of the defined benefit obligation is as follows: 1 April 2012  (Transition date) 2013 2014 Discount rate (%) Japan 1.2%–2.0% 0.8%–1.0% 0.8%–1.0% Overseas 3.4%–5.7% 3.2%–4.8% 3.4%–4.5% 2013 2014 Japan 12.9 years 12.8 years Overseas 19.2 years 20.1 years Financial Section Annual Report 2014 _  Astellas Pharma Inc.  137